Will regn stock rise or fall over the next month?
Out of 516 instances in the last ten years that REGN stock saw a twenty-one day decline of 6% or more, 312 of them resulted in REGN stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 312 out of 516, or about a 60% chance of a rise in REGN stock over the coming month.
Why is Regeneron (regn) stock down 6%?
The stock price of Regeneron has seen a 6% fall over the last twenty-one trading days, while it is down 7% over the last week. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail.
Where can I buy regn shares?
Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is Regn a good buy?
Out of 15 analysts, 5 (33.33%) are recommending REGN as a Strong Buy, 5 (33.33%) are recommending REGN as a Buy, 3 (20%) are recommending REGN as a Hold, 2 (13.33%) are recommending REGN as a Sell, and 0 (0%) are recommending REGN as a Strong Sell. What is REGN's earnings growth forecast for 2022-2024?
Is Regn a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is REGN overvalued?
Price to Book Ratio PB vs Industry: REGN is overvalued based on its Price-To-Book Ratio (3.6x) compared to the US Biotechs industry average (1.5x).
Does REGN have dividend?
REGN Regeneron Pharmaceuticals, Inc. REGN does not currently pay a dividend.
Will REGN stock go up?
Stock Price Forecast The 20 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 707.50, with a high estimate of 790.00 and a low estimate of 536.00. The median estimate represents a +16.23% increase from the last price of 608.71.
How do I buy stock in Regeneron?
You can purchase stock in our company through a registered brokerage or stock purchase service provider of your choice. You cannot buy Regeneron stock directly from the company.
Is Regeneron stock undervalued?
Severe undervaluation of REGN I believe REGN is severely undervalued by the market at this point. On every relevant valuation metric, it's far below the sector median: P/E ratio at 10.31, EV/Sales at 4.74, and Price/Sales at 4.93.
Is Regeneron stock a buy right now?
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.65, and is based on 12 buy ratings, 4 hold ratings, and 1 sell rating.
Is Regeneron stock overvalued?
Regeneron Pharmaceuticals Stock Is Estimated To Be Modestly Undervalued. The stock of Regeneron Pharmaceuticals (NAS:REGN, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation.
Does Vertex pay a dividend?
VERTEX PHARMACEUTICALS (NASDAQ: VRTX) does not pay a dividend.
Is Regeneron Pharmaceuticals a buy right now?
17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are c...
When is Regeneron Pharmaceuticals' next earnings date?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecas...
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported $11...
What price target have analysts set for REGN?
17 Wall Street analysts have issued 12-month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $575.00 to $844.00. On...
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the following people: Dr. Leonard S. Schleifer M.D. , Ph.D., Founder, Pres, CEO & Director (...
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?
423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87%...
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Bi...
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NV...
What is Regeneron Pharmaceuticals' stock symbol?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Nasdaq Global Select
Environmental, Social, and Governance Rating
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Latest Stocks Videos
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Zacks
In The Money: Groundhog Day: Mega-Cap Tech Stocks Out From the Shadows? Feb 02, 2022
